LY75: A Protein Involved in Immune Response and Cell Growth (G4065)

Target Name: LY75

NCBI ID: G4065

LY75

LY75: A Protein Involved in Immune Response and Cell Growth

LY75, also known as CD205, is a protein that is expressed in a variety of tissues throughout the body, including the brain, lungs, liver, and plasma cells. It is a member of the B cell maturation antigen (BCMA) family, which includes proteins that are expressed in the plots of mature B cells, such as CD205.

The BCMA family is a subfamily of the B cell maturation antigen (BCMA) family, which is a glycoprotein that is expressed in the plots of mature B cells. The BCMA protein is a transmembrane protein that contains an extracellular domain, a transmembrane domain, and an intracellular domain. The intracellular domain is responsible for the interaction with the cell surface and for the functions of the protein, such as cell adhesion, migration, and signaling.

LY75 is a glycoprotein that is made up of a single polypeptide chain. It has a molecular weight of approximately 75 kDa and a calculated pI of around 5.6. LY75 is expressed in a variety of tissues throughout the body, including the brain, lungs, liver , and plasma cells.

One of the functions of LY75 is that it is involved in the regulation of the immune response. It is a receptor for the T cell receptor alpha chain, which is responsible for the recognition of foreign antigens by T cells. LY75 is also a receptor for the B cell receptor, which is responsible for the signaling of B cells to the plasma cells that produce antibodies.

Another function of LY75 is that it is involved in the regulation of cell growth and differentiation. It is a negative regulator of the cell cycle, which means that it promotes the stay in G1 phase and inhibits the stay in S phase. This helps to ensure that cells divide in a controlled and orderly manner and that they do not undergo apoptosis.

LY75 is also involved in the regulation of inflammation. It is a potent stimulator of the production of pro-inflammatory cytokines, such as TNF-alpha, IL-12, and IL-18. This helps to promote the recruitment of immune cells to the site of inflammation and to facilitate the recruitment of antigens to the site of infection.

LY75 is also a potential drug target. Its expression in various tissues makes it a promising target for small molecule inhibitors. Additionally, its functions in cell growth, differentiation, and inflammation make it a potential biomarker for a variety of diseases, including cancer, autoimmune diseases, and inflammatory disorders.

In conclusion, LY75 is a protein that is expressed in a variety of tissues throughout the body and is involved in the regulation of the immune response, cell growth and differentiation, and inflammation. Its functions as a potential drug target and biomarker make it an attractive target for small molecule inhibitors. Further research is needed to fully understand the role of LY75 in the immune response and to determine its potential as a drug.

Protein Name: Lymphocyte Antigen 75

The "LY75 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LY75 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets